Technical Analysis for SGMO - Sangamo BioSciences, Inc.

Grade Last Price % Change Price Change
grade F 8.69 0.70% 0.06
SGMO closed up 0.7 percent on Wednesday, October 23, 2019, on 83 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Earnings due: Nov 6

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Up
See historical SGMO trend table...

Date Alert Name Type % Chg
1,2,3 Retracement Bearish Bearish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
20 DMA Support Bullish 0.00%
Stochastic Reached Overbought Strength 0.00%
Weak + Overbought Other 0.00%
Overbought Stochastic Strength 0.00%
Up 3 Days in a Row Strength 0.00%
Crossed Above 20 DMA Bullish 0.70%
Narrow Range Bar Range Contraction 2.60%
NR7 Range Contraction 2.60%

Older signals for SGMO ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Sangamo BioSciences, Inc., a clinical stage biopharmaceutical company, focuses on the research, development, and commercialization of zinc finger DNA-binding proteins (ZFPs) for gene regulation and gene modification in the United States. Its ZFPs could be engineered to make ZFP nucleases (ZFNs) proteins, which could be used to modify DNA sequences in various ways; and ZFP transcription factors (ZFP TFs) proteins that could be used to turn genes on or off. The company's principal ZFP therapeutic is SB-728-T, a ZFN-modified autologous T-cell product, which is in Phase II and Phase I/II clinical trials for the treatment of human immunodeficiency virus and acquired immunodeficiency syndrome. It also develops SB-313xTZ that is in Phase I clinical trial for the treatment of glioblastoma. In addition, the company has ZFP therapeutic pre-clinical stage programs for hemophilia A and B, and huntington's disease; and proprietary programs in the areas of hemoglobinopathies and lysosomal storage disorders. Further, it has ZFP therapeutic research stage programs in the areas of other monogenic diseases, including certain immunodeficiency disorders. The company has collaboration, research, and license agreements with Shire AG; Sigma-Aldrich Corporation; Dow AgroSciences LLC; Genentech, Inc.; Open Monoclonal Technology, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. Sangamo Biosciences, Inc. was founded in 1995 and is headquartered in Richmond, California.
Biotechnology Life Sciences Emerging Technologies Molecular Biology Glioblastoma Huntington's Disease Hemoglobinopathies Hemophilia A Hoffmann La Roche Lysosomal Storage Disorders
Is SGMO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 5 bearish and 0 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 14.53
52 Week Low 6.26
Average Volume 1,103,703
200-Day Moving Average 10.4677
50-Day Moving Average 9.9762
20-Day Moving Average 8.542
10-Day Moving Average 8.375
Average True Range 0.391
ADX 47.17
+DI 14.047
-DI 26.3187
Chandelier Exit (Long, 3 ATRs ) 9.627
Chandelier Exit (Short, 3 ATRs ) 8.873
Upper Bollinger Band 9.2541
Lower Bollinger Band 7.8299
Percent B (%b) 0.6
BandWidth 16.67291
MACD Line -0.4397
MACD Signal Line -0.5599
MACD Histogram 0.1203
Fundamentals Value
Market Cap 728.84 Million
Num Shares 83.9 Million
EPS -0.81
Price-to-Earnings (P/E) Ratio -10.73
Price-to-Sales 42.92
Price-to-Book 5.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.13
Resistance 3 (R3) 9.11 8.94 9.05
Resistance 2 (R2) 8.94 8.83 8.95 9.03
Resistance 1 (R1) 8.82 8.76 8.88 8.84 9.00
Pivot Point 8.65 8.65 8.69 8.66 8.65
Support 1 (S1) 8.53 8.54 8.59 8.55 8.38
Support 2 (S2) 8.36 8.47 8.37 8.35
Support 3 (S3) 8.24 8.36 8.33
Support 4 (S4) 8.26